Company / Shareholders' Equity
NEKTAR THERAPEUTICS Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$89.8M
FY2025
5-year range
$89.8M / $679.5M
FY2021-FY2025
Trend
-31.4%
vs FY2024
Sector context
#174 of 213
Health Care
What the data says
NEKTAR THERAPEUTICS's shareholders' equity of $90M is lower than 82% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from $36M in FY2016 to $1.7B in FY2020.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of -44.6%.
Declined from $367M to $90M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -37.4%
- 5-Year CAGR
- -44.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 213This company $89.8M Sector average $2.5B
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -44.6%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 31.4% year-over-year.
- Ranks #174 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.8M | -31.4% |
| FY2024 | $131.0M | -64.3% |
| FY2023 | $366.6M | +0.0% |
| FY2022 | $366.6M | -46.0% |
| FY2021 | $679.5M | -60.4% |
| FY2020 | $1.7B | +1855.6% |
| FY2019 | $87.8M | -0.3% |
| FY2018 | $88.1M | +0.3% |
| FY2017 | $87.8M | +141.7% |
| FY2016 | $36.3M | +465.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026